AZN
ASTRAZENECA PLC
NYSE: AZN · Cambridge · Healthcare
$171.49-1.08 (-0.63%)Closed
Market Cap—
Cash—most recent
Runway—
P/E (TTM)—
52-Wk Range$155.62 – $208.62
Avg Volume2.8M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$171.49+16.6%
Pipeline
Drug candidates sponsored by ASTRAZENECA · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | quetiapine fumarate | Schizophrenia+2 more | Completed | 2009-07past | 2 | |
| Phase 4 | Quetiapine fumarate (Seroquel XR) | Acute Bipolar Mania | Terminated | 2011-03past | 1 | |
| Phase 4 | Seroquel XR- quetiapine fumarate extended release | Schizophrenia | Completed | 2011-08past | 1 | |
| Phase 4 | ticagrelor | Non-ST Elevation Acute Coronary Syndrome+1 more | Completed | 2015-04past | 2 | |
| Phase 4 | Sodium Zirconium Cyclosilicate (SZC) | Hyperkalaemia+1 more | Completed | 2024-12-10past | 1 | |
| Phase 4 | Pulmicort (budesonide) Turbuhaler | Asthma | Completed | — | 1 | |
| Phase 3 | ARIMIDEX (anastrazole) | Breast Cancer | Completed | 2003-01past | 1 | |
| Phase 3 | SEROQUEL (quetiapine fumarate) Tablets | Bipolar Disorder+1 more | Completed | 2003-09past | 1 | |
| Phase 3 | AC2993 | Diabetes Mellitus, Type 2 | Completed | 2005-09past | 1 | |
| Phase 3 | NXY-059 | Cerebral Stroke+3 more | Completed | 2006-09past | 1 | |
| Phase 3 | Exenatide (AC2993) | Diabetes Mellitus, Type 2 | Completed | 2008-07past | 1 | |
| Phase 3 | Dapagliflozin | Type 2 Diabetes | Completed | 2009-08past | 1 | |
| Phase 3 | exenatide | Type 2 Diabetes Mellitus+1 more | Completed | 2009-12past | 2 | |
| Phase 3 | Quetiapine Fumarate Extended- Release | Schizophrenia | Completed | 2010-07past | 1 | |
| Phase 3 | Esomeprazole | Stress Ulcer Prophylaxis+1 more | Completed | 2016-02past | 2 | |
| Phase 3 | budesonide/formoterol 'as needed' + budesonide placebo bid | Asthma | Completed | 2017-08-16past | 1 | |
| Phase 3 | Durvalumab (MEDI4736) | Non-muscle-invasive Bladder Cancer | Active, not recruiting | 2025-04-03past | 1 | |
| Phase 3 | Medi-546 | Systemic Lupus Erythematosus | Active, not recruiting | 2025-08-22past | 1 | |
| Phase 3 | Olaparib | Breast Cancer Metastatic+4 more | Active, not recruiting | 2026-07-27past | 4 | |
| Phase 3 | Ropivacaine | Anesthesia,Spinal | Completed | — | 1 | |
| Phase 2 | Aclidinium bromide and formoterol | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2008-11past | 1 | |
| Phase 2 | AZD1656 | Type II Diabetes Mellitus+1 more | Completed | 2011-02past | 2 | |
| Phase 2 | Gefitinib 250mg | Lung Cancer | Completed | 2014-07past | 1 | |
| Phase 2 | Placebo | Non-alcoholic Fatty Liver Disease (NAFLD+1 more | Completed | 2016-05-26past | 1 | |
| Phase 2 | Durvalumab and Tremelimumab | Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma | Completed | 2020-06-22past | 1 | |
| Phase 2 | Acalabrutinib | COVID-19 | Completed | 2020-11-17past | 1 | |
| Phase 1 | Part A:Placebo | Dyslipidemia | Completed | 2022-09-10past | 1 | |
| Phase 2 | Osimertinib + Savolitinib | Non-Small Cell Lung Cancer | Active, not recruiting | 2022-12-21past | 1 | |
| Phase 2 | Brazikumab | Ulcerative Colitis+1 more | Terminated | 2023-10-23past | 1 | |
| Phase 2 | AZD4831 | Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis+1 more | Completed | 2024-04-04past | 2 | |
| Phase 2 | AZD2693 | Nonalcoholic Steatohepatitis | Completed | 2025-07-14past | 1 | |
| Phase 2 | AZD2389 | Liver Fibrosis+2 more | Completed | 2025-08-24past | 2 | |
| Phase 2 | AZD5004 | Obesity or Overweight | Completed | 2025-11-21past | 1 | |
| Phase 2 | AZD4144 | Sepsis+1 more | Recruiting | 2027-02-11 | 1 | |
| Phase 2 | Osimertinib | Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting | 2027-10-01 | 1 | |
| Phase 2 | Gefitinib | Prostate Cancer+1 more | Completed | — | 2 | |
| Phase 2 | Fulvestrant | Breast Cancer+1 more | Completed | — | 2 | |
| Phase 1 | AZD6370 | Type 2 Diabetes | Completed | 2008-06past | 1 | |
| Phase 1 | AZD6280 | Anxiety | Completed | 2008-09past | 1 | |
| Phase 1 | AZD6140 | Renal Impairment | Completed | 2008-09past | 1 | |
| Phase 1 | CP-675,206 | Melanoma | Terminated | 2010-01past | 1 | |
| Phase 1 | NKTR-118 | Amount of NKTR-118 in Blood+4 more | Completed | 2012-04past | 2 | |
| Phase 1 | Naloxegol | Drug Induced Constipation | Completed | 2012-08past | 1 | |
| Phase 1 | Fostamatinib | Rheumatoid Arthritis | Completed | 2013-01past | 1 | |
| Phase 1 | Ticagrelor 90 mg whole tablet | Bioavailability Heathy Volunteers | Completed | 2013-09past | 1 | |
| Phase 1 | AZD4721 | Chronic Obstructive Pulmonary Disease (COPD). | Completed | 2014-06past | 1 | |
| Phase 1 | Clopidogrel | Bioequivalence, AUC, Cmax, Pharmacokinetics | Completed | 2014-10past | 1 | |
| Phase 1 | AZD2014 | Advanced Metastatic Breast Cancer | Completed | 2016-08-04past | 1 | |
| Phase 1 | AZD9291 tablet dosing | Solid Tumours | Completed | 2017-05-16past | 1 | |
| Phase 1 | AZD9977 | Healthy Volunteers | Completed | 2018-06-13past | 1 | |
| Phase 1 | Intravenous Infusion | Asthma | Completed | 2019-07-05past | 1 | |
| Phase 1 | AZD4041 | Opioid Use Disorder (OUD) | Completed | 2022-06-07past | 1 | |
| Phase 1 | Tezepelumab | Asthma | Completed | 2022-09-27past | 1 | |
| Phase 1 | AZD3152 (Cohort 1) | COVID-19, SARS-CoV-2 | Completed | 2024-12-05past | 1 | |
| Phase 1 | Administration of ceralasertib | Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer | Active, not recruiting | 2025-03-04past | 1 | |
| Phase 1 | AZD5492 | Systemic Lupus Erythematosus+2 more | Recruiting | 2027-05-05 | 1 | |
| Phase 1 | AZD8529 | Healthy Volunteer | Completed | — | 1 | |
| Phase 1 | AZD2066 | Pain | Completed | — | 1 | |
| Phase 1 | AZD2624 | Healthy+1 more | Completed | — | 1 | |
| N/A | Unnamed | Bipolar Depression | Completed | 2007-10past | 1 | |
| N/A | Unnamed | Schizophrenia+1 more | Completed | 2007-11past | 1 | |
| N/A | Unnamed | Hypertension | Completed | 2009-03past | 1 | |
| N/A | Unnamed | Dyslipidemia | Completed | 2010-08past | 1 | |
| N/A | Unnamed | Gastroesophageal Reflux | Completed | 2010-09past | 1 | |
| N/A | Unnamed | Myocardial Infarction | Completed | 2010-11past | 1 | |
| N/A | Unnamed | Schizophrenia | Completed | 2010-11past | 1 | |
| N/A | Unnamed | Non-psychotic Unipolar Major Depression | Completed | 2014-09past | 1 | |
| N/A | Unnamed | Acute Coronary Syndrome | Completed | 2014-09past | 1 | |
| N/A | Unnamed | Diabetes Mellitus, Type 2 | Completed | 2016-09-01past | 1 | |
| N/A | Unnamed | Reflux Esophagitis | Completed | 2017-02-20past | 1 | |
| N/A | Unnamed | Non-Small Cell Lung Cancer | Completed | 2020-03-19past | 1 | |
| N/A | Unnamed | COVID-19 | Completed | 2023-05-25past | 1 | |
| N/A | Evusheld | COVID-19 | Completed | 2024-01-09past | 1 | |
| N/A | Unnamed | NSCLC | Completed | 2024-07-16past | 1 | |
| N/A | Unnamed | Systemic Lupus Erythematosus | Completed | 2025-09-19past | 1 | |
| N/A | Unnamed | Cancer | Completed | 2025-12-31past | 1 | |
| N/A | Unnamed | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2026-06-22past | 1 | |
| N/A | Unnamed | Uncontrolled Asthma | Active, not recruiting | 2026-09-30past | 1 | |
| N/A | Unnamed | Metastatic Prostate Cancer | Not yet recruiting | 2027-03-31 | 1 | |
| N/A | Unnamed | COPD | Recruiting | 2027-10-21 | 1 | |
| N/A | TDxd | Breast Cancer | Recruiting | 2029-03-31 | 1 | |
| N/A | Unnamed | Rare Diseases+1 more | Recruiting | 2029-12-31 | 1 | |
| N/A | Unnamed | Neurofibromatosis Type 1 (NF1) | Recruiting | 2030-12-31 | 1 | |
| N/A | Unnamed | Dyslipidemia | Completed | — | 1 | |
| N/A | Unnamed | Acute Coronary Syndrome+1 more | Withdrawn | — | 1 | |
| N/A | Unnamed | Hypercholesterolaemia | Completed | — | 1 | |
| N/A | Unnamed | Gastroesophageal Reflux Disease | Completed | — | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for AZN. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.